Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Santen Eyes Pterygium Drug as Key Pipeline Asset, 4 Million Potential Patients in Japan
Santen Pharmaceutical has highlighted its investigational pterygium therapy STN10142 as a promising pipeline candidate, targeting a potential patient population of around 4 million in Japan. At an online R&D briefing on March 19, the ophthalmology specialist framed the drug —…
To read the full story
Related Article
- Santen, RemeGen Win China Filing Acceptance for RC28-E in DME
October 1, 2025
- Santen Secures Asia Rights to RemeGen’s VEGF/FGF Eye Drug RC28-E
August 20, 2025
- Santen Snags Asian Rights to Cloudbreak’s Topical Pterygium Drug
August 7, 2024
BUSINESS
- Tremfya SC Induction Seen Cutting Hospital Time in UC: Expert
March 24, 2026
- Padcev-Keytruda under EMA Review for Cisplatin-Eligible Perioperative MIBC
March 24, 2026
- Nippon Kayaku, GlycoNex Ink Pact on Next-Gen ADC Candidate
March 24, 2026
- Celltrion Wins First Xolair Biosimilar Approval in Japan, Targets May Listing
March 24, 2026
- Roche-Chugai Drops Emugrobart for SMA, FSHD; Obesity Program to Continue
March 24, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…